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Introduction
Mesenchymal stem cells (MSCs) reside in small num-
bers in bone marrow (BM) as well as other tissues and
have been shown to be relatively easy to expand ex
vivo [1,2]. SCs differentiate in vitro and in vivo into
different connective tissue cells types including
osteoblasts, adipocytes, chondrocytes, endothelial and
myogenic cells [3-7]. This multidifferentiation poten-
tial of MSCs raised a clinical interest to use these cells
for regeneration purposes e.g., in treating osteogenesis
imperfecta, stroke or myocardial infarction. MSCs
also lack MHC-II antigens and possess immunomodu-
latory properties, which enable them to treat acute
graft-versus-host disease (GvHD) after hematopoietic
transplantation [8-12].
MSCs can be identified by their ability to adhere to
plastic as well as to grow into colony forming units-
fibroblast (CFU-F) in vitro. However, these cells are
heterogeneous with respect to their proliferation and
differentiation capacity [13,14]. To define this popula-
tion more precisely, surface markers that are enriched
in MSCs, such as CD105 (SH2, endoglin), CD73
(SH3/SH4), SSEA-4, STRO-1 and CD271 (the low
affinity nerve growth factor receptor), have been used
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[15-17]. To date, only a few markers have been devel-
oped and proved suitable for the isolation of MSCs
from primary tissues. Markers that meet established
criteria for their positive selection include STRO-1,
CD73, CD105 and CD271, whereas CD45 and CD235
(glycophorin A) are used for the negative selection of
MSCs [6,18-22]. The International Society for Cellu-
lar Therapy (ISCT) proposed three minimal criteria for
defining MSCs: 1) these cell population must be plas-
tic-adherent when maintained in standard culture con-
ditions using tissue culture flasks; 2) ≥95% of the
MSCs population must express CD105, CD73 and
CD90, as measured by flow cytometry and lack
expression (≤52% positive) of CD45, CD34, CD14 or
CD11b, CD79a or CD19 and HLA class II; and 3)
MSCs must be able to differentiate to osteoblasts,
adipocytes and chondroblasts under standard in vitro
differentiating conditions [23,24]. 
In this work, we have considered the use of 5 mon-
oclonal antibodies that are recommended by the ISCT
[23]: two positive markers of MSCs (CD90 and
CD105) and three negative markers of MSCs (CD34,
CD45 and CD79). We tested if appropriate expression
of these established MSC markers correlates with
CD271 expression alone. Our results indicate that
CD271 expression is a specific marker for the identifi-
cation of fresh bone marrow MSCs. Using CD271 as
the sole marker for MSC identification would reduce
reagent costs and may potentially accelerate the iden-
tification of MSCs for cellular therapy.
Materials and methods
Isolation of bone marrow mononuclear cells. Adult human
mononuclear cells (MNCs) were isolated from the bone marrow
(BM) of 25 healthy volunteer donors after informed consent was
obtained. A total of 4 to 5 ml of BM was obtained by aspiration
from the posterior iliac crest under local anesthesia, according to
standard institutional procedures. MNCs were isolated by density
gradient centrifugation (LymphoprepTM, AXIS-SHIELD PoC AS,
Norway). Briefly, 2 volumes of BM were added to 1 volume of
Lymphoprep and centrifuged at 1500 rpm for 30 minutes. MNCs
were then resuspended before cytometry in 1 ml of Dulbecco's
Phosphate Buffered Saline (GIBCO, InvitrogenTM, USA).
Characterization of MSCs immunophenotype. For fluores-
cence-activated cell analysis, the following antibodies were used:
CD45 PE-TR (Caltag Laboratories U.S.A.), CD34 PE-Cy5 (Caltag
Laboratories U.S.A.), CD79 alpha/APC (Dako, Denmark), CD90
FITC (Dako, Denmark), CD105 PE (eBioscience, U.S.A.), and
separately CD271 (LNGFR) FITC (Miltenyi Biotec, U.S.A.). 
Flow cytometry. A total of 1 × 106 cells were resuspended in 50
μl of Dulbecco's Phosphate Buffered Saline (PBS) and incubated
with 10 μl of antibody for 30 minutes in the dark at room temper-
ature. Cells were resuspended in 1 ml of Dulbecco's PBS and ana-
lyzed immediately. The analysis was performed on a Dako
Cytomation flow cytometer (CyAnADP, Dako Colorado, Inc.
U.S.A.). Calibration of the instrument was performed before data
acquisition using well-established protocols. The software pro-
gram Summit (Dako Cytomation) was used for the acquisition of
50,000 total cells. Data analysis was performed using Summit v4.3
(Dako Cytomation).
Statistical analysis. Statistical analyses of the differences between
the two groups of used markers were performed using a Pearson´s
correlation test. 
Results
Immunophenotype
We hypothesized that CD271 can be used as the sole
marker for MSCs derived from BM. To test this, we
isolated the MNC fraction from BM, incubated these
cells with established cellular markers for MSCs and
compared them to cells isolated by CD271 expression
alone.  As recommended by the ISCT for identifying
MSCs, we sorted cells for the presence of the markers
CD90 and CD105 and the absence of the markers
CD45, CD34 and CD79. We then tested if the isolated
population of MSCs correlated to the population iden-
tified by CD271 expression (Fig. 1). We found that the
average percentage of isolated MNCs from BM that
were CD90+, CD105+, CD45-, CD34- and CD79- was
0.54%, and that the average percentage of the popula-
tion that was CD271+ was 0.53% (Fig. 2). A two-tailed
Pearson's correlation test of 25 replicated experiments
indicated that the correlation between these popula-
tions was significant (p<0.05). These results strongly
suggest that CD271 alone is sufficient to identify
MSCs. 
Discussion
MSCs are marrow-derived progenitor cells that have
been extensively investigated and characterized by
their ability to self-renew and differentiate into multi-
ple lineages including osteoblasts, adipocytes, fibrob-
lasts, and chondrocytes [6,7,12-14,19]. The isolation
procedure for MSCs continues to be based on their
plastic adherence properties [7,25-28]. In addition, the
nomenclature used to distinguish between isolated
cells types is lacking. In an attempt to standardize
nomenclature, the ISCT proposed in a position paper
that cultured MSCs should be designated "multipoten-
tial mesenchymal stromal cells" whereas the term
"mesenchymal stem cells" should be reserved for cells
from primary tissues that can give rise to "colony-
forming units-fibroblasts (CFU-F)" [6,13]. Later, the
ISCT proposed minimal criteria to define human
MSCs, as previously described [23]. 
Though MSCs are routinely isolated from MNCs
primarily by plastic adherence, some authors have
studied the CD271 marker as a specific indicator of the
MSCs. Quirici et al. used CD271 to purify MSCs from
adult BM and compared CD271 expression with CD45
expression and plastic adherence [19]. Jarocha et al.
also considered CD271 as an indicator of MSCs and
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Fig. 1. MSC antigen expression. Analysis of mononuclear cells from bone marrow by flow cytometry. Six representative analysis out of
25 total experiments are shown comparing the percentage of CD90+, CD105+, CD34-, CD45- and CD79- cells with the percentage of
CD271+ cells. The result from a Pearson's correlation test was significant (p<0.05).
compared the differentiation capacity of CD271+ cells
with cells expressing other markers such CD105 as
well as with BM enriched for MSCs by RosetteSep
Isolation Kit and non-purified bone marrow mononu-
clear cells (BMMNC). They concluded that MSCs can
be defined by the following parameters: a) their effica-
cy to form CFU-F colonies; b) their expression of
MSCs-associated antigens (CD105, CD166, CD44,
CD73, CD45, CD34) and genes (e.g. RUNX2,
PPARγ2, osteocalcin, N-cadherin); and c) their
adipocyto/osteogenic potential in vitro [7]. In a sepa-
rate study, Battula et al. used CD271 expression
together with the property of plastic adherence (CFU-
F) to isolate of a new subset of MSCs [14]. Poloni et
al. used CD271 to isolate MSCs from BM and showed
it was feasible to expand MSCs in medium supple-
mented with 10% pooled allogeneic human serum
without loss of multipotent differentiation capacity or
karyotype alterations [29]. Until recently, CD271 has
been described as the most selective marker for the
characterization and purification of human Bone Mar-
row-Mesenchymal Stem Cell [6]. Likewise, Zhou et
al. proposed to detect the expression of CD271,
CD133 and CD34 and to analyze the correlation of
CD271 with CD133 as well as CD133 with CD34
expression by flow cytometry with three color fluores-
cence labeling. They concluded that CD271+ cells are
different from CD133+ and CD34+ cells, which sug-
gests that CD271 might have an important role in eval-
uating MSCs and therefore guiding their future clinical
application [30]. 
Conclusions
The objective of this study was to analyze the correla-
tion of CD271 expression with the positive expression
of CD90, CD105 markers as well as the negative
expression of CD34, CD45 and CD79 markers on cells
from fresh human BM. Our goal was to determine the
feasibility of using CD271 expression as a marker for
MSCs and to demonstrate that the exclusive use of this
marker is sufficient to identify MSCs from fresh sam-
ples of BM cells. BMCs and MNCs were detected by
flow cytometry. We found in 25 samples of fresh BM
that the correlation between the previously established
markers and CD271 expression as assessed by a Pear-
son's test was highly significant (p<0.05). These
results agree with the works of Battula, Buhring,
Jarocha, and Poloni which also used the CD271 mark-
er as a reference to isolate and to identify MSCs.
Because some cellular therapy treatments start with
fresh BM, the ability to quantify MSCs quickly is
essential. Furthermore, the use of a single marker to
identify MSCs allows for a convenient, stream-lined
protocol without the extensive analysis required by
using a series of defined markers and without requir-
ing culture in plastic dishes. In addition, we have
demonstrated that CD271 expression alone can substi-
tute for established phenotypic markers in isolating
MSCs. 
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